PubMed ID:
14727931
Public Release Type:
Journal
Publication Year: 2003
Affiliation: Emory University School of Medicine, Atlanta, GA, USA. jlea@emory.edu
DOI:
https://doi.org/10.2165/00129784-200303030-00005
Authors:
AASK Study Group,
Brown DT,
Lea JP,
Lipkowitz M,
Middleton J,
Norris K
Strategies to delay progression of established renal disease have primarily been directed at examining the class of antihypertensive therapy and/or the level of blood pressure control. In diabetic renal disease many trials have noted a protective role of ACE inhibitor-based therapy over non-ACE inhibitor-based therapy. This paper reviews recent clinical trials evaluating hypertension-related kidney disease including the interim results of the African-American Study of Kidney Diseases and Hypertension (AASK) Study, to date the largest prospective study of African-American patients with kidney disease due to hypertension. This trial reports a renoprotective effect of ACE inhibitor-based therapy over calcium-channel antagonist- based therapy. The renoprotective effect of ACE inhibitor-based therapy may, in part, be due to their antiproteinuric effect independent of blood pressure lowering.